Summary
Vertex Pharmaceuticals Inc. (VRTX) reported its quarterly results for the period ending June 30, 2005. The company continues to operate at a net loss, with a loss of $40.99 million for the quarter and $85.71 million for the first six months of the year. Despite the losses, Vertex experienced significant revenue growth, with total revenues increasing by 71% to $32.32 million for the quarter and by 61% to $60.93 million for the six-month period. This growth was driven by increased royalties and collaborative research and development revenues, reflecting new collaboration agreements. Operationally, Vertex is significantly increasing its investment in the development of VX-950, an oral inhibitor for Hepatitis C virus (HCV) infection, following positive Phase Ib trial results. The company also provided financial guidance for the full year 2005, expecting a net loss between $140 million and $150 million and total revenues between $150 million and $160 million. Vertex raised approximately $165.3 million in net proceeds from a public stock offering in June 2005, bolstering its cash position to $446.6 million in cash, cash equivalents, and available-for-sale securities as of June 30, 2005. The company anticipates continued significant investments in its pipeline and expects to incur losses for the foreseeable future, while also exploring additional capital transactions.
Key Highlights
- 1Total revenues increased significantly, up 71% year-over-year to $32.3 million for the quarter and up 61% year-over-year to $60.9 million for the six months ended June 30, 2005.
- 2Collaborative research and development revenue was a key driver of growth, increasing substantially due to new collaboration agreements signed in late 2004 and early 2005.
- 3Net loss for the quarter was $40.99 million, a slight improvement from $44.27 million in the prior year's quarter, but the six-month net loss widened slightly to $85.71 million from $84.71 million.
- 4Vertex is substantially increasing investment in VX-950, an oral HCV protease inhibitor, following positive Phase Ib clinical trial results showing significant viral load reduction.
- 5The company successfully completed a public offering in June 2005, raising approximately $165.3 million in net proceeds, significantly strengthening its cash position to $446.6 million.
- 6Full-year 2005 financial guidance anticipates a net loss between $140 million and $150 million and total revenues between $150 million and $160 million.
- 7Research and development expenses increased by 25% year-over-year for the quarter to $59.36 million, primarily driven by investments in VX-950 and VX-702 clinical programs.